Uridine triacetate
Clinical data | |
---|---|
Trade names | Vistogard, Xuriden |
Other names | vistonuridine |
AHFS/Drugs.com | Monograph |
MedlinePlus | a616020 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Pyrimidine catabolic pathway |
Onset of action | Tmax = 2–3 hours |
Elimination half-life | 2–2.5 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.021.710 |
Chemical and physical data | |
Formula | C15H18N2O9 |
Molar mass | 370.314 g·mol−1 |
3D model (JSmol) | |
| |
|
Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used:
- in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/ ZOOR-ə-den);[3]
- to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).[4][5][6][7][8]
Uridine triacetate was developed, manufactured and distributed by . It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.[9][10][11]
References[]
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. p. 92. Retrieved 12 March 2017.
- ^ "Uridine triacetate — DrugBank Page". 12 March 2017.
- ^ "Xuriden- uridine triacetate granule". DailyMed. 16 December 2019. Retrieved 20 October 2020.
- ^ "Vistogard- uridine triacetate granule". DailyMed. 15 November 2018. Retrieved 20 October 2020.
- ^ "BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd. 11 December 2015. Retrieved 12 March 2017.
- ^ "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. Archived from the original on 3 March 2016. Retrieved 12 March 2017.
- ^ Cada DJ, Mbogu U, Bindler RJ, Baker DE (June 2016). "Uridine Triacetate". Hospital Pharmacy. 51 (6): 484–8. doi:10.1310/hpj5106-484. PMC 4911989. PMID 27354750.
- ^ Ison G, Beaver JA, McGuinn WD, Palmby TR, Dinin J, Charlab R, et al. (September 2016). "FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs". Clinical Cancer Research. 22 (18): 4545–4549. doi:10.1158/1078-0432.CCR-16-0638. PMID 27401247.
- ^ "Xuriden (uridine triacetate) oral granules". U.S. Food and Drug Administration (FDA). 8 October 2015. Archived from the original on 8 December 2019. Retrieved 7 December 2019. This article incorporates text from this source, which is in the public domain.
- ^ "Drug Trials Snapshots: Xuriden". U.S. Food and Drug Administration (FDA). 4 September 2015. Archived from the original on 8 December 2019. Retrieved 8 December 2019. This article incorporates text from this source, which is in the public domain.
- ^ "Previous Cumulative CY CDER BT Approvals" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original on 8 December 2019. Retrieved 7 December 2019. This article incorporates text from this source, which is in the public domain.
External links[]
- "Uridine triacetate". Drug Information Portal. U.S. National Library of Medicine.
Categories:
- Acetate esters
- Antidotes
- Breakthrough therapy
- Prodrugs
- Gastrointestinal system drug stubs